Indian Court Says "No" To Linking Patents With Regulatory Approvals; Sends Back Six Patent Oppositions
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In two back-to-back judgments delivered by the Delhi High Court this week, multinational drug companies Bayer and Eli Lilly suffered major setbacks as the Indian court rejected their separate pleas - one related to the linkage of patent grants with regulatory approvals and the other a re-examination of the existing system for patent oppositions
You may also be interested in...
India's Cipla Not Ready For U.S. Biosimilars Market Even As Peers Line Up For Bigger Piece Of Pie
MUMBAI - Cipla - India's largest drug maker by market share - will not be amongst the first bunch of companies that prepare to launch biosimilars in the U.S
India's Cipla Not Ready For U.S. Biosimilars Market Even As Peers Line Up For Bigger Piece Of Pie
MUMBAI - Cipla - India's largest drug maker by market share - will not be amongst the first bunch of companies that prepare to launch biosimilars in the U.S
Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions
MUMBAI - In a landmark decision that will further restrict multinational drug companies from introducing their internationally marketed brands in India, the Delhi High Court rejected German drug maker Bayer's plea to stop the Drug Controller General of India - the Indian drug regulator - from granting marketing approval to generic drug maker Cipla for kidney/liver cancer drug Nexavar (sorafenib)